Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer
2024 · npj Breast Cancer · 7 citations
https://doi.org/10.1038/s41523-024-00676-w
R
Rafael Dal Ponte Ferreira
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
35
Papers
251
Citations
7
h-index
5
i10-index
Rafael Dal Ponte Ferreira is an academic researcher from Hospital Moinhos de Vento. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Prostate Cancer Treatment and Research & Prostate Cancer Diagnosis and Treatment. The author has an h-index of 7, co-authored 30 publications.
ORCID: 0000-0001-5910-1808Papers by this author
worksPathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study
2025 · Breast Cancer Research and Treatment · 5 citations
https://doi.org/10.1007/s10549-025-07628-3
Study Participants1 from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
2024 · 0 citations
https://doi.org/10.1158/1078-0432.27938292
Supplementary Figure 4B from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
2024 · 0 citations
https://doi.org/10.1158/1078-0432.27938262
Supplementary Methods1 from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
2024 · 0 citations
https://doi.org/10.1158/1078-0432.27938256
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat